Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Holding KROS?
Track your performance easily
KROS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.67 - $73.00
Previous Close$17.03
Volume1.47M
Average Volume (3M)804.48K
Market Cap
$685.39M
Enterprise Value$173.97M
Total Cash (Recent Filing)$530.70M
Total Debt (Recent Filing)$19.29M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Feb 27, 2025EPS Estimate
-$1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.21
Shares Outstanding40,507,409
10 Day Avg. Volume2,958,635
30 Day Avg. Volume804,481
Standard Deviation0.20
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.29
Price to Sales (P/S)1052.82
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue267.24
Enterprise Value/Gross Profit1.15K
Enterprise Value/Ebitda-1.25
Forecast
1Y Price Target
$53.33Price Target Upside213.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Keros Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe $200M upfront payment provides a strong booster to the balance sheet, which will support a runway into 4Q28.
Product Safety And EfficacyCibotercept for PAH has shown better safety than an approved drug, with none of the side effects observed in a completed Ph1 study.
Strategic PartnershipsThe partnership with Takeda for elritercept verifies elritercept's differentiated profile and a significant market potential.
Bears Say
Clinical TrialsThe unexpected safety signal and changes to KROS’ Phase 2 TROPOS study of cibotercept in pulmonary arterial hypertension significantly increases the clinical, regulatory, and commercial risk for this asset.
Safety ConcernsKeros announced that it was voluntarily halting the two higher-dosing arms of TROPOS, a phase 2 of cibotercept in PAH due to the emergence of pericardial effusion side effects.
Stock PerformanceThe announcement confounded the Street's and analyst's thesis toward the program which ultimately resulted in the stock closing -73.15%.
---
Ownership Overview
8.69% Insiders
21.83% Mutual Funds
37.52% Other Institutional Investors
21.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $15.67 and its highest was $73.00 in the past 12 months.
What is Keros Therapeutics’s market cap?
Currently, no data Available
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Nov 06, 2024. The company reported -$1.41 earnings per share for the quarter, missing the consensus estimate of -$1.279 by -$0.131.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -$1.36.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 40,507,410 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.41 in its last earnings report, missing expectations of -$1.279. Following the earnings report the stock price went up 1.084%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Among the largest hedge funds holding Keros Therapeutics’s share is Woodline Partners LP. It holds Keros Therapeutics’s shares valued at 44M.
---
Keros Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$53.33 (213.15% Upside)
$53.33 (213.15% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 57.3%
Last 30 Days ▲ 57.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.58%
12-Months-Change
Fundamentals
Return on Equity
-43.82%
Trailing 12-Months
Asset Growth
77.56%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
---
KROS Stock 12 Month Forecast
Average Price Target
$53.33
▲(213.15% Upside)
Technical Analysis
Best Analysts Covering KROS
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+5.12%
assigned a buy rating 6 days ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +5.12% per trade.
---